Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment.

Scientific reports - 29 Jul 2024

Castaldo Alice, Iacotucci Paola, Bagnasco Sveva, Fevola Cristina, Carnovale Vincenzo, Antonelli Fabio, Cernera Gustavo, Gelzo Monica, Terlizzi Vito

Abstract excerpt

Modulators of cystic fibrosis transmembrane conductance regulator (CFTR) improved cystic fibrosis (CF) patients' outcome. The elexacaftor/tezacaftor/ivacaftor (ETI) combination was safe and effective improving lung function in patients with different CFTR genotypes, including at least one F508del mutation. However, cases with liver damage were reported. We describe 105 CF patients heterozygous for F508del in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Combinations

Share to Indoles

Share to Pyrazoles

Share to Pyridines

Share to Pyrrolidines

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 39075279
DOI: 10.1038/s41598-024-68511-7
PMCID: PMC11286749

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment.PMID 39075279Read ↗

Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis.Semantic proximity Read ↗

Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor TreatmentSemantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations.Semantic proximity Read ↗

Experience With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Disease.Semantic proximity Read ↗

Impaired cholesterol metabolism in the mice model of cystic fibrosis. A vicious circle?Semantic proximity Read ↗

Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis.Semantic proximity Read ↗

Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators.Semantic proximity Read ↗

Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control StudySemantic proximity Read ↗

The combination elexacaftor/tezacaftor/ivacaftor (ETI) modulates the de novo synthethic pathway of ceramides in a genotype-independent manner.Semantic proximity Read ↗

Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A preliminary study.Semantic proximity Read ↗

Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM.Semantic proximity Read ↗

Elexacaftor-Tezacaftor-Ivacaftor As A Final Frontier in The Treatment of Cystic Fibrosis: Definition of The Clinical and Microbiological Implications in A Case-Control StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.